Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Diabetic retinopathy: Classification and clinical features

Claire E Fraser, MD, PhD
Donald J D'Amico, MD
Section Editors
David M Nathan, MD
Jonathan Trobe, MD
Deputy Editor
Jean E Mulder, MD


Diabetic retinopathy (DR) is one of the most important causes of visual loss worldwide, and is the principal cause of impaired vision in patients between 25 and 74 years of age. Visual loss from DR may be secondary to macular edema (ME; retinal thickening and edema involving the macula), hemorrhage from new vessels, retinal detachment, or neovascular glaucoma.

The vast majority of patients who develop DR have no symptoms until the very late stages (by which time it may be too late for effective treatment). Because the rate of progression may be rapid, and therapy can be beneficial for both symptom amelioration and reduction in the rate of disease progression, it is important to screen patients with diabetes regularly for the development of retinal disease.

The classification, clinical features, and natural history of DR will be reviewed here. The pathogenesis, screening, and treatment of DR are discussed elsewhere (see "Diabetic retinopathy: Pathogenesis" and "Diabetic retinopathy: Screening" and "Diabetic retinopathy: Prevention and treatment"). Cataracts associated with diabetes are also a major cause of visual impairment, especially in type 2 diabetes. Cataracts are reviewed separately. (See "Cataract in adults".)


Diabetic retinopathy (DR) is divided into two major forms: nonproliferative and proliferative, named for the absence or presence of abnormal new blood vessels emanating from the retina. DR can be further classified by severity (table 1 and picture 1 and picture 2). These stratifications have been useful for analysis of treatment efficacy in the literature and general indicators for treatment strategies. However, each patient with DR has a unique combination of findings, symptoms, and rate of progression, which necessarily requires an individualized approach to treatment in the effort to preserve vision.

Nonproliferative retinopathy — Nonproliferative diabetic retinopathy (NPDR) consists of a variable display of nerve-fiber layer infarcts (cotton wool spots), intraretinal hemorrhages, and hard exudates, and microvascular abnormalities (including microaneurysms, occluded vessels, and dilated or tortuous vessels) primarily in the macula and posterior retina (picture 3). Visual loss in NPDR is primarily through the development of macular edema (ME). (See 'Macular edema' below.)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 24, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003; 136:122.
  2. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350:48.
  3. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996; 97:2883.
  4. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102:527.
  5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.
  6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.
  7. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169:1307.
  8. Lecaire T, Palta M, Zhang H, et al. Lower-than-expected prevalence and severity of retinopathy in an incident cohort followed during the first 4-14 years of type 1 diabetes: the Wisconsin Diabetes Registry Study. Am J Epidemiol 2006; 164:143.
  9. LeCaire TJ, Palta M, Klein R, et al. Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 2013; 36:631.
  10. Sloan FA, Belsky D, Ruiz D Jr, Lee P. Changes in incidence of diabetes mellitus-related eye disease among US elderly persons, 1994-2005. Arch Ophthalmol 2008; 126:1548.
  11. Vallance JH, Wilson PJ, Leese GP, et al. Diabetic retinopathy: more patients, less laser: a longitudinal population-based study in Tayside, Scotland. Diabetes Care 2008; 31:1126.
  12. Leske MC, Wu SY, Hennis A, et al. Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados Eye Studies. Ophthalmology 2005; 112:799.
  13. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116:874.
  14. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5:1390.
  15. Jervell J, Moe N, Skjaeraasen J, et al. Diabetes mellitus and pregnancy--management and results at Rikshospitalet, Oslo, 1970-1977. Diabetologia 1979; 16:151.
  16. Moloney JB, Drury MI. The effect of pregnancy on the natural course of diabetic retinopathy. Am J Ophthalmol 1982; 93:745.
  17. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990; 13:34.
  18. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care 1995; 18:631.
  19. Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000; 23:1084.
  20. Schocket LS, Grunwald JE, Tsang AF, DuPont J. The effect of pregnancy on retinal hemodynamics in diabetic versus nondiabetic mothers. Am J Ophthalmol 1999; 128:477.
  21. Rajala U, Pajunpää H, Koskela P, Keinänen-Kiukaanniemi S. High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care 2000; 23:957.
  22. Chew EY, Ferris FL 3rd, Csaky KG, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology 2003; 110:1683.
  23. Klein BE, Klein R, McBride PE, et al. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Arch Intern Med 2004; 164:1917.
  24. van Hecke MV, Dekker JM, Stehouwer CD, et al. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care 2005; 28:1383.
  25. Targher G, Bertolini L, Zenari L, et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Diabet Med 2008; 25:45.
  26. Kramer CK, Rodrigues TC, Canani LH, et al. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care 2011; 34:1238.